IZOTROPIC CORP. Total Liabilities
IZOTROPIC CORP. total liabilities. Based on the latest financial reports, IZOTROPIC CORP. (1R3) has total liabilities worth €6.06 Million EUR (≈ $7.09 Million USD) as of April 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See IZOTROPIC CORP. (1R3) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of IZOTROPIC CORP. (2022–2026)
Total liabilities of IZOTROPIC CORP. from 2022 to 2026. This chart illustrates how IZOTROPIC CORP.'s total liabilities have evolved over time, based on quarterly financial data.
IZOTROPIC CORP. Competitors by Total Liabilities
The table below lists competitors of IZOTROPIC CORP. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Immuron Ltd ADR
NASDAQ:IMRN
|
USA | $2.06 Million |
|
Sewon E&C
KO:091090
|
Korea | ₩110.01 Billion |
|
Masonglory Limited Ordinary Shares
NASDAQ:MSGY
|
USA | $379.55K |
|
Bulletin Resources Ltd
AU:BNR
|
Australia | AU$1.23 Million |
|
Activeport Group Ltd
AU:ATV
|
Australia | AU$5.57 Million |
|
Natural Health Trend
NASDAQ:NHTC
|
USA | $14.01 Million |
|
Postmedia Network Canada Corp
TO:PNC-B
|
Canada | CA$626.48 Million |
|
Max Resource Corp
V:MAX
|
Canada | CA$2.13 Million |
Liability Composition Analysis (2022–2026)
This chart breaks down IZOTROPIC CORP.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 1R3 total asset value.
Liquidity & Leverage Metrics
IZOTROPIC CORP. Total Liabilities Ratios Explained
IZOTROPIC CORP. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 13.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IZOTROPIC CORP.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IZOTROPIC CORP. (2022–2026)
The table below shows the annual total liabilities of IZOTROPIC CORP. from 2022 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-04-30 | €6.06 Million ≈ $7.09 Million |
+15.00% |
| 2025-04-30 | €5.27 Million ≈ $6.17 Million |
+29.30% |
| 2024-04-30 | €4.08 Million ≈ $4.77 Million |
+16.01% |
| 2023-04-30 | €3.52 Million ≈ $4.11 Million |
+32.99% |
| 2022-04-30 | €2.64 Million ≈ $3.09 Million |
-- |
About IZOTROPIC CORP.
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a breast CT imaging system. The company was incorporated in 2016 and is headquartered in Surrey, Canada.